John R Teerlink

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
    John R Teerlink
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    Lancet 381:29-39. 2013
  2. ncbi The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT
    John R Teerlink
    San Francisco Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA 94121 1545, USA
    Drug Saf 35:233-44. 2012
  3. ncbi Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
  4. ncbi Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
  5. ncbi A novel approach to improve cardiac performance: cardiac myosin activators
    John R Teerlink
    University of California, San Francisco, USA
    Heart Fail Rev 14:289-98. 2009
  6. ncbi Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
  7. ncbi Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    Lancet 373:1429-39. 2009
  8. ncbi The development of new medical treatments for acute decompensated heart failure
    John R Teerlink
    University of California, San Francisco, CA, USA
    Heart Fail Monit 2:129-37. 2002
  9. ncbi Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, USA
    Heart Fail Rev 14:243-53. 2009
  10. ncbi Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure
    Barry M Massie
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    N Engl J Med 363:1419-28. 2010

Detail Information

Publications24

  1. ncbi Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
    John R Teerlink
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    Lancet 381:29-39. 2013
    ..The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would have greater dyspnoea relief compared with patients treated with standard care and placebo...
  2. ncbi The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT
    John R Teerlink
    San Francisco Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA 94121 1545, USA
    Drug Saf 35:233-44. 2012
    ..Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes...
  3. ncbi Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
    ..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...
  4. ncbi Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
    ..Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure...
  5. ncbi A novel approach to improve cardiac performance: cardiac myosin activators
    John R Teerlink
    University of California, San Francisco, USA
    Heart Fail Rev 14:289-98. 2009
    ..These studies suggest that cardiac myosin activators offer the promise of a safe and effective treatment for heart failure. A program of clinical studies are being planned to test whether CK-1827452 will fulfill that promise...
  6. ncbi Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
    ..This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings...
  7. ncbi Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    Lancet 373:1429-39. 2009
    ..We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety...
  8. ncbi The development of new medical treatments for acute decompensated heart failure
    John R Teerlink
    University of California, San Francisco, CA, USA
    Heart Fail Monit 2:129-37. 2002
    ..These three agents represent a new generation of therapeutics for this important medical problem and may provide the means not only to treat symptoms, but also to improve longer-term clinical outcomes...
  9. ncbi Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, USA
    Heart Fail Rev 14:243-53. 2009
    ....
  10. ncbi Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure
    Barry M Massie
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    N Engl J Med 363:1419-28. 2010
    ....
  11. ncbi Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    Am Heart J 150:46-53. 2005
    ..Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated...
  12. ncbi Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure
    Guillermo Torre-Amione
    Section of Cardiology, Methodist DeBakey Heart Center and Baylor College of Medicine, Texas Medical Center, One Baylor Plaza, Houston, TX 77030, USA
    J Am Coll Cardiol 42:140-7. 2003
    ..We sought to investigate the efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized for acute heart failure (HF)...
  13. ncbi Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction
    Marina R Bergman
    Department of Medicine, San Francisco Department of Veterans Affairs Medical Center University of California, San Francisco, California 94121, USA
    Am J Physiol Heart Circ Physiol 292:H1847-60. 2007
    ..5 +/- 1.5 vs. MMP 4.7 +/- 2.0; P = 0.016). Expression of active MMP-2 is sufficient to induce severe ventricular remodeling and systolic dysfunction in the absence of superimposed injury...
  14. ncbi Overview of randomized clinical trials in acute heart failure syndromes
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, California 94121 1545, USA
    Am J Cardiol 96:59G-67G. 2005
    ....
  15. ncbi A rational approach for the treatment of acute heart failure: current strategies and future options
    Madan Sharma
    Section of Cardiology, San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California San Francisco School of Medicine, USA
    Curr Opin Cardiol 19:254-63. 2004
    ..A number of new agents are under investigation with the goal of improving patient outcomes...
  16. ncbi Role of tolvaptan in acute decompensated heart failure
    Jennifer E Ho
    University of California, San Francisco, CA, USA
    Expert Rev Cardiovasc Ther 6:601-8. 2008
    ....
  17. ncbi The role of endothelin in the pathogenesis of heart failure
    John R Teerlink
    Department of Cardiology, 111C, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121 1545, USA
    Curr Cardiol Rep 4:206-12. 2002
    ..Clinical studies to date have not fulfilled this promise. Further analysis of these trials will hopefully provide insight into these disparate findings and guidance for future investigations...
  18. ncbi Endothelins: pathophysiology and treatment implications in chronic heart failure
    John R Teerlink
    Cardiology, 111C, San Francisco VAACE Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Curr Heart Fail Rep 2:191-7. 2005
    ..Further analysis of the data from these trials, as well as other ongoing studies, may provide insight into these disparate findings and guidance for future investigations...
  19. ncbi Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure
    John R Teerlink
    Heart Failure Clinic, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, School of Medicine, San Francisco, Calif 94121-1545, USA
    Am Heart J 145:S26-33. 2003
  20. ncbi Nesiritide: a reappraisal of efficacy and safety
    Sanjiv J Shah
    University of California, Division of Cardiology, Department of Medicine, San Francisco, USA
    Expert Opin Pharmacother 8:361-9. 2007
    ..A large outcomes trial in patients with ADHF would help clarify the role of nesiritide...
  21. ncbi Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury
    Bo-qing Zhu
    Cardiology Section, VA Medical Center, Department of Medicine, University of California-San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    J Cardiovasc Pharmacol Ther 11:119-28. 2006
    ..Combination therapy further reduces infarct size. PQQ is superior to metoprolol in protecting mitochondria from ischemia/reperfusion oxidative damage...
  22. ncbi Reversal of left ventricular remodeling: role of the endothelin pathway
    John R Teerlink
    University of California and the Heart Failure Clinic, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Card Fail 8:S494-9. 2002
    ..This review discusses this role of the endothelin pathway in the development of left ventricular remodeling and the evidence that endothelin antagonists can reverse this deleterious process...
  23. ncbi Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?
    John R Teerlink
    School of Medicine, University of California, and the Section of Cardiology, Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    J Card Fail 8:124-7. 2002
  24. ncbi The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?
    Mary Rose Fabi
    San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Curr Heart Fail Rep 2:59-64. 2005
    ..This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients...